Logo yposkesi
waves image

Your CDMO partner of choice for Viral Vector Manufacturing

Yposkesi’s virtual tour

Who we are

Yposkesi, an SK pharmteco company, is one of Europe’s largest Contract Development and Manufacturing Organizations (CDMO) for cell and gene therapy viral vector manufacturing.

As a trusted partner for biotech and pharmaceutical companies seeking to advance clinical trials and commercialize new Advanced Therapy Medicinal Products (ATMPs), Yposkesi offers a full range of services in lentiviral vectors and AAV (Adeno-Associated Virus) cGMP manufacturing. Within its current 50,000 sq ft. (approx. 5,000 m2) facility, Yposkesi operates multiple manufacturing suites for bulk drug substance (up to 1,000 L) and fill and finish to support the growing demand for late-phase projects. In 2023, Yposkesi will bring online additional capacity by increasing its global footprint to 100,000 sq ft. (approx. 10,000 m2) with a second large-scale facility designed for EMA and FDA compliance.

Yposkesi’s investment in innovation ensures that its bioprocessing platforms deliver high quality gene-modified cell therapies and in vivo gene therapy projects.

Yposkesi’s staff of ~200 employees is located on the Genopole Campus in Corbeil-Essonnes (South of Paris), France.

Bioprocess development (USP & DSP)

We use innovation to reach new heights in production efficiency.

Discover

cGMP manufacturing of clinical and commercial viral vector batches

Our extensive AAV and lentiviral vector manufacturing capacity helps ensure on-time deliver.

Learn more

Analytical development, assays qualification & validation

Our experts aim to satisfy all your analytical needs with high quality.

Discover

Fill & Finish

We offer a variety of cGMP compliant vials filling format for Fill & Finish.

Learn more

Regulatory support

We provide strategic, technical and regulatory support.

Discover

Partnering to bring your Cell and Gene therapies to life...

Growing Capacity

Time is of essence in the clinical development of new therapies, and manufacturing is often a real bottleneck for cell and gene therapy products.  At Yposkesi, we have one of the largest AAV (Adeno-Associated Virus) and lentiviral vector production capacities in Europe. Our growing cGMP facilities, dedicated manpower, and expertise allow us to easily accommodate new projects and meet the timeline and budget for your breaking ground in therapeutic treatments.

Learn more about us
Yposkesi services

Trusted partner

Yposkesi is a trusted partner with both technical expertise and a long-term commitment to quality.
Our services encompass process development, cGMP manufacturing of AAV and lentiviral vectors, Fill & Finish, QC, QA, and regulatory support. We aim to establish an open and trustworthy relationship with you with the ultimate goal of reducing time-to-market and ensuring an uninterrupted supply of viral vectors.

Discover what’s possible
Gene therapy Innovation

Innovation

There is a significant industrial challenge to overcome the manufacturing costs of gene therapy products.
As a leading CDMO, Yposkesi is at the forefront of designing new techniques that improve process robustness and scalability, thereby increasing productivity. We have a highly-skilled and dedicated innovation team focused on your evolving needs and requirements for a committed, sustainable, and competitive AAV and lentiviral vector supply.

Find out how we innovate

Would you like to know more?

Contact us